Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects (Q35959473)

11 August 2017

1 reference

title

Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects (English)

1 reference

11 August 2017

0 references

Bacigalupo A

1

1 reference

PubMed ID

15558041

11 August 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

Bone Marrow Transplantation

11 August 2017

1 reference

11 August 2017

35

1 reference

11 August 2017

3

1 reference

11 August 2017

225-231

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704758

11 August 2017

0 references

cites work

A survey of diagnosis, management, and grading of chronic GVHD.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

Antithymocyteglobulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-cell—depleted grafts from matched unrelated donors: A dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

Effect of antithymocyte globulin on quantitative immune recovery and graft-versus-host disease after partially T-cell-depleted bone marrow transplantation: a comparison between recipients of matched related and matched unrelated donor grafts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

A randomized study of the prevention of acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

7 January 2021

Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

7 January 2021

Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

7 January 2021

In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

7 January 2021

ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

7 January 2021

Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

7 January 2021

Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

7 January 2021

A prospective analysis of immune recovery in children following allogeneic transplantation of t-cell-depleted or non-T-cell-depleted hematopoietic cells from HLA-disparate family donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

7 January 2021

Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

7 January 2021

Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

7 January 2021

One antigen mismatched related donor bone marrow transplant in a patient with acute lymphoblastic leukaemia and beta-thalassaemia major: potential cure of both marrow disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

7 January 2021

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

7 January 2021

Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704758

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704758

1 reference

PubMed ID

15558041

Dimensions Publication ID

11 August 2017

0 references

1 reference

PubMed ID

15558041